Extrovis, Dr Reddy’s Launch Generic Fluorouracil Cream In US market

KUALA LUMPUR, Aug 19 (Bernama) -- Extrovis AG, a global pharmaceutical firm, and Dr Reddy’s Laboratories Ltd have launched Fluorouracil Cream, 0.5 per cent, an authorised generic and therapeutic equivalent of Carac, in the United States (US).

In a statement, Extrovis said the cream is approved by the US Food and Drug Administration (USFDA), and it is used to treat multiple actinic or solar keratoses on the face and scalp.

Manufactured in Texas at an Extrovis facility, the launch is a result of a partnership that combines Extrovis’ research and development (R&D) and manufacturing prowess with Dr Reddy’s established US market reach.

Extrovis Co-Chief Executive Officer and Chief Strategy Officer, Hans R. Kamma said the launch marks an important step in improving patient access and supporting the US healthcare system.

“Our partnership with Dr Reddy’s helps ensure that patients and healthcare providers in the US have continued access to a high-quality and cost-effective product,” he said.

Meanwhile, Extrovis Chief Financial Officer, Raghavendra Rao PV, said Dr Reddy’s expertise in the US market distribution and commercialisation strengthens the collaboration.

“This collaboration is aligned with our mission to strengthen pharmaceutical supply chains and serve public health needs responsibly,” stated Rao.

The collaboration also aligns with Extrovis’ long-term strategy to expand the reach of its therapeutic products while enhancing affordability and sustainability in healthcare.

Dr Reddy’s Fluorouracil Cream, 0.5 per cent, is supplied in a 30-gramme tube for topical use only.

-- BERNAMA